Cargando…

Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia

BACKGROUND: In several countries, the dolutegravir (DTG)-based regimen is generally preferred as first-line antiretroviral therapy (ART) over the efavirenz (EFV)-based regimen, but the evidence in low-income countries is limited. OBJECTIVE: Our study aimed to evaluate the cost effectiveness of DTG-...

Descripción completa

Detalles Bibliográficos
Autores principales: Belay, Yared Belete, Ali, Eskinder Eshetu, Chung, Karen Y., Gebretekle, Gebremedhin Beedemariam, Sander, Beate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611130/
https://www.ncbi.nlm.nih.gov/pubmed/34133017
http://dx.doi.org/10.1007/s41669-021-00275-6
_version_ 1784603238872383488
author Belay, Yared Belete
Ali, Eskinder Eshetu
Chung, Karen Y.
Gebretekle, Gebremedhin Beedemariam
Sander, Beate
author_facet Belay, Yared Belete
Ali, Eskinder Eshetu
Chung, Karen Y.
Gebretekle, Gebremedhin Beedemariam
Sander, Beate
author_sort Belay, Yared Belete
collection PubMed
description BACKGROUND: In several countries, the dolutegravir (DTG)-based regimen is generally preferred as first-line antiretroviral therapy (ART) over the efavirenz (EFV)-based regimen, but the evidence in low-income countries is limited. OBJECTIVE: Our study aimed to evaluate the cost effectiveness of DTG- versus EFV-based first-line human immunodeficiency virus (HIV) treatment in Ethiopia. METHODS: We developed a microsimulation model for the progression of HIV/acquired immune deficiency syndrome (AIDS) to examine the cost effectiveness of DTG-based first-line ART compared with an EFV-based regimen from a healthcare payer perspective. We used a lifetime horizon with a 1-month cycle length and a 3% annual discount rate. The primary outcomes were a lifetime cost in US dollars ($), quality-adjusted life-months (QALMs) that converted to QALYs using the formula QALY = QALM/12, and incremental cost-effectiveness ratio (ICER). Deterministic sensitivity analysis was conducted to account for parameter uncertainty. RESULTS: Compared with the EFV-based regimen, the DTG-based regimen was associated with an expected lifetime cost of $12,709 (vs. $12,701) and expected QALYs of 15.3 (vs. 14.7 QALYs) per patient, resulting in an ICER value of $13.33 per QALY. From an alternative analysis with a 5-year time horizon, DTG-based ART was found to be dominant, with expected gains of 0.17 QALYs at a lower cost of $1 per patient. The deterministic sensitivity analysis depicted that the maximum increase in ICER value was $72 per QALY, and all ICER values were below the estimated threshold value. CONCLUSIONS: The DTG-based first-line regimen appears to be cost effective compared with the EFV-based regimen for the treatment of HIV/AIDS patients in an Ethiopian setting.
format Online
Article
Text
id pubmed-8611130
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-86111302021-12-10 Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia Belay, Yared Belete Ali, Eskinder Eshetu Chung, Karen Y. Gebretekle, Gebremedhin Beedemariam Sander, Beate Pharmacoecon Open Original Research Article BACKGROUND: In several countries, the dolutegravir (DTG)-based regimen is generally preferred as first-line antiretroviral therapy (ART) over the efavirenz (EFV)-based regimen, but the evidence in low-income countries is limited. OBJECTIVE: Our study aimed to evaluate the cost effectiveness of DTG- versus EFV-based first-line human immunodeficiency virus (HIV) treatment in Ethiopia. METHODS: We developed a microsimulation model for the progression of HIV/acquired immune deficiency syndrome (AIDS) to examine the cost effectiveness of DTG-based first-line ART compared with an EFV-based regimen from a healthcare payer perspective. We used a lifetime horizon with a 1-month cycle length and a 3% annual discount rate. The primary outcomes were a lifetime cost in US dollars ($), quality-adjusted life-months (QALMs) that converted to QALYs using the formula QALY = QALM/12, and incremental cost-effectiveness ratio (ICER). Deterministic sensitivity analysis was conducted to account for parameter uncertainty. RESULTS: Compared with the EFV-based regimen, the DTG-based regimen was associated with an expected lifetime cost of $12,709 (vs. $12,701) and expected QALYs of 15.3 (vs. 14.7 QALYs) per patient, resulting in an ICER value of $13.33 per QALY. From an alternative analysis with a 5-year time horizon, DTG-based ART was found to be dominant, with expected gains of 0.17 QALYs at a lower cost of $1 per patient. The deterministic sensitivity analysis depicted that the maximum increase in ICER value was $72 per QALY, and all ICER values were below the estimated threshold value. CONCLUSIONS: The DTG-based first-line regimen appears to be cost effective compared with the EFV-based regimen for the treatment of HIV/AIDS patients in an Ethiopian setting. Springer International Publishing 2021-06-16 /pmc/articles/PMC8611130/ /pubmed/34133017 http://dx.doi.org/10.1007/s41669-021-00275-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Belay, Yared Belete
Ali, Eskinder Eshetu
Chung, Karen Y.
Gebretekle, Gebremedhin Beedemariam
Sander, Beate
Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
title Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
title_full Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
title_fullStr Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
title_full_unstemmed Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
title_short Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
title_sort cost-utility analysis of dolutegravir- versus efavirenz-based regimens as a first-line treatment in adult hiv/aids patients in ethiopia
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611130/
https://www.ncbi.nlm.nih.gov/pubmed/34133017
http://dx.doi.org/10.1007/s41669-021-00275-6
work_keys_str_mv AT belayyaredbelete costutilityanalysisofdolutegravirversusefavirenzbasedregimensasafirstlinetreatmentinadulthivaidspatientsinethiopia
AT alieskindereshetu costutilityanalysisofdolutegravirversusefavirenzbasedregimensasafirstlinetreatmentinadulthivaidspatientsinethiopia
AT chungkareny costutilityanalysisofdolutegravirversusefavirenzbasedregimensasafirstlinetreatmentinadulthivaidspatientsinethiopia
AT gebreteklegebremedhinbeedemariam costutilityanalysisofdolutegravirversusefavirenzbasedregimensasafirstlinetreatmentinadulthivaidspatientsinethiopia
AT sanderbeate costutilityanalysisofdolutegravirversusefavirenzbasedregimensasafirstlinetreatmentinadulthivaidspatientsinethiopia